Thromboprophylaxis in Medical Patients

Introduction to Thromboprophylaxis

• The standard prophylactic dose of 5,000 IU of heparin can be safely used as thromboprophylaxis in dialysis patients, as recommended by multiple guidelines, including those from the American Heart Association and American College of Chest Physicians 1, 2

Dosing Regimens

• For thromboprophylaxis, 5,000 IU of heparin subcutaneously every 8-12 hours is the standard prophylactic dose recommended by multiple guidelines, including those from the American Heart Association and American College of Chest Physicians 1, 2
• Unfractionated heparin (UFH) is preferred over low molecular weight heparin (LMWH) in patients with severe renal impairment (CrCl <30 mL/min) due to its hepatic clearance, with a standard prophylactic dose of 5,000 units subcutaneously every 8 hours, as recommended by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the American College of Chest Physicians 3, 4, 5, 6
• Alternative pharmacological options include:

Monitoring and Management

• Monitor platelet counts regularly to detect heparin-induced thrombocytopenia (HIT), particularly between days 4-14 of therapy, as recommended by the American Society of Hematology 7
• The following table outlines the actions to take based on aPTT levels:

• The risk of heparin-induced thrombocytopenia (HIT) is higher with UFH (up to 5%) compared to LMWH 7

Contraindications and Precautions

• Absolute contraindications to pharmacological prophylaxis include active major bleeding, recent central nervous system bleeding, severe thrombocytopenia, and lumbar puncture/spinal analgesia expected within 12 hours or performed within last 4 hours (24 hours if traumatic) 8
• Relative contraindications include chronic, clinically significant bleeding, thrombocytopenia, severe platelet dysfunction, recent major operation at high risk for bleeding, underlying hemorrhagic coagulopathy, and high risk for falls with potential head trauma, as stated by the American College of Cardiology 6

Alternative Methods

• If heparin is contraindicated, consider mechanical thromboprophylaxis methods, as suggested by the American College of Chest Physicians 9
• Fondaparinux may be an option for thromboprophylaxis in dialysis patients, though it has limited data, according to the National Comprehensive Cancer Network 10
• Regional citrate anticoagulation can be considered for patients at high bleeding risk, as recommended by the American College of Radiology 11
• Mechanical prophylaxis with graduated compression stockings is not recommended as a standalone intervention due to lack of efficacy and potential for skin damage, as stated by the American College of Physicians 12
• Intermittent pneumatic compression devices may be considered as an alternative for patients at high risk of bleeding where heparin is contraindicated 12, 8
• Anti-embolic stockings may be added, though evidence for their efficacy alone is limited 8

Duration of Prophylaxis

• Continue prophylaxis until the patient is fully ambulatory or until hospital discharge, with a minimum recommended duration of 7 days for high-risk patients, as recommended by the Society of Critical Care Medicine 4
• Pharmacological thromboprophylaxis should be initiated within 24 hours after bleeding has been controlled in patients at significant risk for VTE, such as those with lumbar osteomyelitis, with a Grade 1B recommendation 8
• For patients with active bleeding or high bleeding risk, mechanical thromboprophylaxis should be used initially 8

Efficacy and Outcomes

• The administration of UFH 5,000 UI every 8 hours has been shown to significantly reduce the risk of deep vein thrombosis (from 73% to 22%) and pulmonary embolism (from 20% to 5%), according to studies published in Circulation and Arteriosclerosis, Thrombosis, and Vascular Biology 13, 6